Improved symptoms following bumetanide treatment in 1 children aged 3 to 6 years with autism spectrum disorder: 2 a randomized, double-blind, placebo-controlled trial 3

Yuan Dai,Lingli Zhang,Juehua Yu,Xin Zhou,Hua He,Yiting Ji,Kai Wang,Xiujuan Du,Xin Liu,Yun Tang,Shining Deng,C. Langley,Wei-Guang Li,Jun Zhang,Jianfeng Feng,B. Sahakian,Qiang Luo,Fei Li

2020-01-01

Abstract:41 With the drug therapy for the core symptoms of autism spectrum disorder (ASD) currently 42 limited, here we reported a randomised, double-blind, placebo-controlled trial to investigate 43 the efficacy, safety, and potential neural mechanism of bumetanide in children with ASD 44 aged 3 to 6 years old. There were 120 children entered into the study and randomly assigned 45 to either 0.5mg bumetanide or placebo. In the final sample, 119 received at least one dose of 46 bumetanide (59 children) or placebo (60 children). The primary outcome was the score 47 reduction of Childhood Autism Rating Scale (CARS) and the secondary outcomes were the 48 score of Clinical Global Impressions Scale (CGI) -Global Improvement (CGI-I) at 3 months 49 and the change from baseline to 3-month in Autism Diagnostic Observation Schedule 50 (ADOS). Magnetic resonance spectroscopy (MRS) was used to measure γ -aminobutyric acid 51 (GABA) and glutamate neurotransmitter concentrations in the insular cortex (IC) before and 52 after the treatment. As compared with the placebo, bumetanide treatment was significantly 53 better in reducing severity. No patient withdrew from the trial due to adverse events. The 54 superiority of bumetanide to placebo in reducing insular GABA, measured using MRS, was 55 demonstrated. The clinical improvement was associated with the decrease in insular GABA 56 in the bumetanide group. In conclusion, this trial in a large group of young children with 57 predominantly moderate and severe ASD demonstrated that bumetanide is safe and effective 58 in improving the core symptoms of ASD. However, the clinical significance remains 59 uncertain and future multi-center clinical trials are required to replicate these findings and 60 confirm the clinical significance using a variety of outcome measures. mixed permutation-based and of the treatment for sex,